Horus ML

www.horusml.com ↗ ·Madrid ·Pre-seed

Horus ML is a Madrid-based health-tech company that builds artificial intelligence and machine learning products for clinical practice, organised around three areas: diagnostic imaging, precision medicine and remote patient monitoring. Its lead product, AItheroscope, analyses a standard retinal fundus photograph in under ten seconds to estimate a patient's risk of subclinical atherosclerosis in primary care, using retinographs already found in many health centres. AItheroscope was clinically validated on more than 1,000 patients at Hospital Universitario Infanta Leonor, is used in 18 clinical centres across Spain and has a distribution agreement covering Mexico and Chile. Its other products include Horus Cardio Monitor for remote monitoring of heart failure, Clover for cancer detection in venous thromboembolism patients and Horus Hydro. The company was founded in Madrid in October 2022 and is funded through CDTI's NEOTEC programme. It won the Best Digital Health Startup award at 4YFN and first prize in Fundación MAPFRE's Social Innovation Awards.

Founded
2022
Founders
5
Total funds raised
—
Rounds
0
SectorsHealthtech, Artificial Intelligence, Medical Imaging, Cardiovascular Diagnostics, Remote Patient Monitoring Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

Carolina Espejo
Co-founder & Medical Lead
Guillem Batiste
Co-founder & CPO
Jesús Prada Alonso
Co-founder & CEO
Miguel Bravo
Co-founder & Deep Learning Expert
Yvonne Gala García
Co-founder & CSO

Global models 5

Digital Diagnostics
It sells autonomous AI that reads retinal photos taken in primary care and other non-eye-care settings (LumineticsCore, formerly IDx-DR) to health systems and clinics, the same way AItheroscope is deployed on retinographs in health centres.
$130MComparable
Airdoc
It sells AI software that reads fundus photos to flag cardiovascular, metabolic and eye disease risk in hospitals, primary care and health-check centres; the figure is the more than RMB 800M of equity it reported raising in seven rounds before its 2021 Hong Kong IPO.
$124MComparable
Eyenuk
United States · www.eyenuk.com ↗
Its EyeArt software analyses standard retinal photographs for disease screening in primary care, and it is developing retinal biomarkers that predict systemic disease, including cardiovascular risk.
$43MComparable
Mediwhale
South Korea · www.mediwhale.com ↗
Its lead product, Reti-CVD, estimates cardiovascular disease risk from a single fundus photograph, which is almost exactly what AItheroscope does, and it sells to clinics and health-screening centres.
$36MComparable
Toku
New Zealand · www.tokueyes.com ↗
Its CLAiR platform, which has FDA Breakthrough Device status, reads routine retinal images in about 20 seconds to estimate cardiovascular risk, hypertension and high cholesterol, and is sold through eye-care and primary-care channels; Topcon Healthcare acquired the company in October 2025.
$10.5MComparable

In the same niche 50 others

Most funded firstSee all 51 in Diagnostics & precision medicine testing →

Investors

No investors found yet.

Funding rounds

No announced rounds on record.
Start typing to search across everything.
↑↓ navigate↵ openesc close? shortcuts
Keyboard shortcuts
/ Ctrl K
Search
j k
Next or previous row
↵
Open the row
Ctrl ↵
Open it in a new tab
[ ]
Previous or next page
?
This list